Work

MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies

Year: 2021

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(21)01843-7

Authors: Deepti Radia, Daniel DeAngelo, Michael W. Deininger, Andreas Reiter, Jayita Sen, Hui Min Lin, Sasa Dimitrijevic, Jason Gotlib

Institutions: Guy's and St Thomas' NHS Foundation Trust, Dana-Farber Cancer Institute, University of Utah, Huntsman Cancer Institute, Heidelberg University, University Medical Centre Mannheim, Blueprint Medicines (United States), Stanford Cancer Institute, Stanford University

Language: English

Topic: Mast cells and histamine

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3197527787

Cites:

Cited by: 6

Related to: 10